Benjamin Cravatt of Scripps Research honored with 2020 Award for Outstanding Achievement in Chemistry in Cancer Research
June 15, 2020
LA JOLLA, CA — The American Association for Cancer Research (AACR) has recognized the pioneering work of chemical biologist Benjamin Cravatt, PhD, with its 2020 Award for Outstanding Achievement in Chemistry in Cancer Research.
The award is intended to credit outstanding, novel, and significant chemistry research that has led to important contributions in basic and translational cancer research, as well as in the diagnosis, prevention and treatment of cancer.
“Ben is a remarkable scientist, whose discoveries in chemistry have been instrumental in identifying new therapeutic drugs for a variety of difficult-to-treat conditions,” says Jamie Williamson, PhD, executive vice president of Research and Academic Affairs at Scripps Research.
AACR recognized Cravatt for his development of activity-based protein profiling, a powerful chemical approach that has enabled the analysis of protein activities on an unprecedented scale. He has applied these creative techniques to characterize key signaling pathways in cancer, demonstrating their potential to serve as therapeutic targets. Subsequently, Cravatt has used cutting-edge profiling methods to develop selective drugs to validate these targets for the diagnosis and treatment of cancer.
Throughout his career, Cravatt has made numerous important breakthroughs spanning the fields of chemical biology, biochemistry, cancer, and neuroscience. He is a professor at the Skaggs Institute for Chemical Biology and the Gilula Chair of Chemical Biology for the Department of Chemistry at Scripps Research.
Expanding the drug target universe
There are countless proteins that play critical roles in disease, yet they remain challenging to target with therapeutics. In this Front Row lecture, Professor Benjamin Cravatt explained how his large-scale protein profiling research and innovative chemical technologies are helping identify novel drugs for therapeutic targets previously deemed ‘undruggable.’ Cravatt’s translational work, which is at the intersection of chemistry and biology, has also led to the formation of multiple local biotechnology companies that collectively employ hundreds of scientists who are developing first-in-class candidate medicines for diverse diseases ranging from cancer to neurological disorders.
Professor Benjamin Cravatt and physician-scientist Lou Lange join Scripps Research Board of Directors
Scripps Research has added Benjamin Cravatt, PhD, professor of Chemistry and the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research, and Lou Lange, MD, PhD, physician-scientist and general partner with Asset Management Ventures, to its Board of Directors.